Data presented by Nazli Dizman at #KCRS24 show that CBM588 prevents the depletion of species previously associated with a better immune checkpoint inhibitor response and corrects gut dysbiosis in patients with mRCC. https://lnkd.in/eW4c6qTp
About us
Urology Times takes the lead in providing news analysis of key advances in surgical and non-surgical techniques, treatments, and practice management. Urology Times has been the #1 read publication for more than 20 years, reaching the full universe of physician-specialists treating urologic disorders. We keep urologists up to date so they can quickly provide better patient care while running a more efficient practice.
- Website
-
http://www.UrologyTimes.com
External link for Urology Times
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Type
- Public Company
- Specialties
- Urology
Employees at Urology Times
Updates
-
Patient enrollment and dosing continue to progress in a phase 1/2 trial of ONCT-534, an investigational dual-action androgen receptor inhibitor for relapsed or refractory mCRPC. https://lnkd.in/eU4NbhDe
Dosing, enrollment progress in phase 1/2 study of ONCT-534 in mCRPC
urologytimes.com
-
Dr. Mantu Gupta discusses totally tubeless percutaneous nephrolithotomy, an advanced approach to kidney stone removal in which no nephrostomy tube and no stent is left in the patient following the procedure. Icahn School of Medicine at Mount Sinai https://lnkd.in/eX3f8KQr
No tubes, no stents: Investigators explore advanced approach to PCNL
urologytimes.com
-
“Our findings suggest an impact of living in disadvantaged neighborhoods—which more commonly affects African Americans—on stress-related genetic pathways in the body. We believe this may increase an individual’s risk of aggressive prostate cancer and contribute to prostate cancer disparities by race,” says Dr. Kathryn Barry. University of Maryland School of Medicine https://lnkd.in/ebP__6bu
Neighborhood disadvantage linked to stress-related genes that may increase prostate cancer risk
urologytimes.com
-
The investigational noradrenaline reuptake inhibitor TAS-303 demonstrated superior efficacy over placebo with a favorable safety profile in patients with SUII, according to data from a phase 2 study. https://lnkd.in/edvVNtJA
Investigational medication shows encouraging efficacy in stress urinary incontinence
urologytimes.com
-
Join us on 7/17 at 6pm ET for an insightful discussion on vaginal estrogen. Ashley Winter MD and Maria Uloko will share their expertise & perspectives. Set a reminder here: https://bit.ly/4cD9ESe #XSpaces #vaginal #estrogen #urology
-
-
Investigators at UCLA have been awarded a grant to support a study assessing biomarkers that may predict which patients are more likely to experience genitourinary toxicity following radiation therapy for prostate cancer. UCLA Health Jonsson Comprehensive Cancer Center | Amar Kishan | Joanne Weidhaas https://lnkd.in/emHqFbGK
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
urologytimes.com
-
CMS has established 3 category 1 CPT codes for the TULSA procedure in patients with prostate diseases. https://lnkd.in/eGdj-WUi
CMS issues category 1 CPT codes for TULSA procedure
urologytimes.com
-
The AUA, GURS, and SUFU have released an amendment to the incontinence after prostate treatment guideline. https://lnkd.in/eVNFygqT
AUA, GURS, SUFU amend guideline for incontinence after prostate treatment
urologytimes.com
-
Dr. Kevin Basralian discusses the current state of focal therapy in prostate cancer. Hackensack Meridian Health | Hackensack Meridian School of Medicine https://lnkd.in/edZDX6nU
Dr. Basralian on the current state of focal therapy in prostate cancer
urologytimes.com